Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib for Cutaneous Neurofibromas in NF1
NCT02839720Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Aug 2017
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selumetinib in neurofibromatosis type 1 (NF1), cutaneous neurofibroma (cNF), sponsored by National Cancer Institute. Started Aug 2017; status: completed.
02
Drugs
selumetinib
03
Conditions
neurofibromatosis type 1 (NF1)cutaneous neurofibroma (cNF)
Beyond the preview
Go deeper on NCT02839720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02839720.